Autologous blood derived cell therapy in maxillofacial bone graft surgery

Tissue regeneration is one of the ultimate goals of maxillofacial surgery and various types of tissue engineering technologies have been utilized in clinics. Healthy resources of host cells and growth factors are essential for the tissue engineering, therefore autologous blood-derived cell therapy w...

Descripción completa

Detalles Bibliográficos
Autor principal: Park, Joo-Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Oral and Maxillofacial Surgeons 2021
Materias:
Editor's Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721413/
https://www.ncbi.nlm.nih.gov/pubmed/34969023
http://dx.doi.org/10.5125/jkaoms.2021.47.6.480
_version_ 1784625336767479808
author Park, Joo-Young
author_facet Park, Joo-Young
author_sort Park, Joo-Young
collection PubMed
description Tissue regeneration is one of the ultimate goals of maxillofacial surgery and various types of tissue engineering technologies have been utilized in clinics. Healthy resources of host cells and growth factors are essential for the tissue engineering, therefore autologous blood-derived cell therapy was introduced. In this article, clinical applications of the autologous platelet concentrates and stem cell separation therapy will be summarized and evaluated for their efficacy and feasibility in the current maxillofacial clinics.
format Online
Article
Text
id pubmed-8721413
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Korean Association of Oral and Maxillofacial Surgeons
record_format MEDLINE/PubMed
spelling pubmed-87214132022-01-11 Autologous blood derived cell therapy in maxillofacial bone graft surgery Park, Joo-Young J Korean Assoc Oral Maxillofac Surg Editor's Opinion Tissue regeneration is one of the ultimate goals of maxillofacial surgery and various types of tissue engineering technologies have been utilized in clinics. Healthy resources of host cells and growth factors are essential for the tissue engineering, therefore autologous blood-derived cell therapy was introduced. In this article, clinical applications of the autologous platelet concentrates and stem cell separation therapy will be summarized and evaluated for their efficacy and feasibility in the current maxillofacial clinics. The Korean Association of Oral and Maxillofacial Surgeons 2021-12-31 2021-12-31 /pmc/articles/PMC8721413/ /pubmed/34969023 http://dx.doi.org/10.5125/jkaoms.2021.47.6.480 Text en Copyright © 2021 The Korean Association of Oral and Maxillofacial Surgeons. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Editor's Opinion
Park, Joo-Young
Autologous blood derived cell therapy in maxillofacial bone graft surgery
title Autologous blood derived cell therapy in maxillofacial bone graft surgery
title_full Autologous blood derived cell therapy in maxillofacial bone graft surgery
title_fullStr Autologous blood derived cell therapy in maxillofacial bone graft surgery
title_full_unstemmed Autologous blood derived cell therapy in maxillofacial bone graft surgery
title_short Autologous blood derived cell therapy in maxillofacial bone graft surgery
title_sort autologous blood derived cell therapy in maxillofacial bone graft surgery
topic Editor's Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721413/
https://www.ncbi.nlm.nih.gov/pubmed/34969023
http://dx.doi.org/10.5125/jkaoms.2021.47.6.480
work_keys_str_mv AT parkjooyoung autologousbloodderivedcelltherapyinmaxillofacialbonegraftsurgery

Ejemplares similares